GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners
International Journal of Biological Sciences · 2026
DOI: 10.7150/ijbs.118985 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Songbo Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Drug Resistance, Neoplasm, Kidney Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Intrinsic resistance to sunitinib in advanced renal cell carcinoma (RCC) remains a major barrier to improving patient survival outcomes. However, the molecular mechanisms driving this resistance remain incompletely elucidated. In this study, we first observed elevated glutamine levels in sunitinib-resistant RCC models; notably, glutamine deprivation substantially impaired the growth and proliferation of RCC cells. We further demonstrated that abnormal upregulation of GFPT2-a key enzyme in glutamine metabolism-was associated with reduced sunitinib sensitivity and enhanced drug resistance in RCC. Mechanistically, we uncovered that GFPT2 modulates cellular O-GlcNAcylation levels, which in turn enhances the stability and nuclear translocation of YAP1-ultimately contributing to reduced sunitinib sensitivity. In addition, we also identified an additional non-metabolic role of GFPT2: it directly interacts with the Kelch domain of KEAP1, thereby reducing NRF2 binding to this domain and suppressing NRF2 ubiquitination-dependent degradation. Consequently, this regulatory cascade dysregulates the transcription of downstream antioxidant genes (e.g., HMOX1 and NQO1), ultimately driving NRF2-dependent sunitinib resistance in RCC. Critically, this KEAP1-NRF2 axis-mediated mechanism operates independently of GFPT2's metabolic role in regulating O-GlcNAcylation. Collectively, our findings demonstrate that GFPT2 modulates sunitinib sensitivity and drives drug resistance in RCC via dual mechanisms: a metabolic pathway (O-GlcNAcylation-YAP1) and a non-metabolic pathway (KEAP1-NRF2). Targeting the non-metabolic functions of GFPT2 thus holds promise for enhancing sunitinib sensitivity in RCC while potentially mitigating treatment-related side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.
- Core Facility Center, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.
Zitieren
APA
Wang, S., Xing, J., Wang, X., Wang, Z., Shao, P., & Miao, C. (2026). GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.118985
Vancouver
Wang S, Xing J, Wang X, Wang Z, Shao P, Miao C. GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.118985
BibTeX
@article{Wang2026,
author = {Wang, Songbo and Xing, Jiajun and Wang, Xiaoyi and Wang, Zengjun and Shao, Pengfei and Miao, Chenkui},
title = {GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners},
journal = {International Journal of Biological Sciences},
year = {2026},
doi = {10.7150/ijbs.118985}
}
EUVIMED